Alkido Pharma Inc. (NASDAQ:AIKI) and its research partner, Cogia BioTech Ltd, have delivered important updates in their efforts to expedite the study of Pancreatic Ductal Adenocarcinoma (PDA) treatments.
Alkido in a research partnership to use AI in finding PDA genetic markers
The company previously reported an execution of a Scientific Research Agreement with Cogia and The University of Texas Southwestern Medical Centre to employ machine learning in finding genetic markers in people that show increased risk of developing pancreatic cancer. Cogia is an AI, Machine Learning, and Big Data software company dedicated to employing powerful algorithms and AI engines to deliver compelling results in drug development. The progressive report Cogia gave to Alkido included cluster identification of markers interacting in signaling pathways that affect PDA survival.
Also, the Alkido received progress updates on the development of tools and products, offering extensive information on PDA markers guiding personalized medicine. Similarly, the company updated in the assembly of survival association of markers into sets to identify novel targets in PDA and information about protein and gene function in human PDA patients and PDA cancer cell lines to assist in prioritizing diagnostic markers.
Cogia capabilities vital to the expansion of PDA diagnostics, prognostics, and therapeutics
Alkido CEO, Anthony Hayes stated that they were delighted with the progress that Cogia has made in the research project and were enthusiastic about developing panels of markers that will rapidly identify patients who have started early pancreatic cancer events. Hayes said that the Diagnostic Assay Application and Prognostic marker Characterization Application products of Cogia offer vital information on antibodies, especially relative to their proteins of over 20,000 antibody reagents.
It also uses unsupervised Cogia ML/AI learning porticos to identify clusters similar to expressed genes and association with PDA subtypes. He added that the tools have established building blocks that the company has continued to believe will be a broader set of usable full-service tools and products for the ongoing and expansion of PDA prognostics, diagnostics, and therapeutics.
